Study identifier:D9266C00001
ClinicalTrials.gov identifier:NCT05460273
EudraCT identifier:N/A
CTIS identifier:N/A
Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
Carcinoma, Non-Small-Cell Lung
Phase 1/2
No
Datopotamab Deruxtecan (Dato-DXd)
All
119
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
Daiichi Sankyo, Inc.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Dato-DXd Arm This single-arm study consists of multiple cohorts, divided by indication. | - |